STAT July 28, 2022
As the biopharmaceutical industry places increased emphasis on improving the diversity of participants in clinical trials to create more equitable drugs, some are questioning this effort. As a biotech executive and a trial participant, I’ve seen firsthand why it’s needed.
A year ago, the industry trade association PhRMA convened more than 150 biopharma organizations for a workshop on clinical trial diversity. Since then, companies have listened to thousands of patients, health care providers, and health equity experts to understand the problem and identify solutions.
In mid-July, PhRMA launched a first-of-its-kind initiative to promote more equitable drug development. The industry is establishing a network of community-based sites for clinical trials to address key barriers to participation, and many companies, including Genentech,...
Today's Sponsors
Today's Sponsor